Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease?☆
To access this article, please choose from the options below
☆ Guest Editor for this manuscript was George A. Beller, MD, University of Virginia Health Sciences Center, Charlottesville, Va.Submitted May 13, 2002; accepted August 21, 2002.
PII: S0002-8703(02)94818-0
doi:10.1016/S0002-8703(02)94818-0
© 2003 Mosby, Inc. All rights reserved.
